FDA Approves Expanded Use of Eculizumab (Soliris) for Pediatric Myasthenia Gravis, Bringing New Treatment Options for Children
March 10, 2025 16:09 ET
|
Muscular Dystrophy Association
New York, March 10, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of...
Findings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalised myasthenia gravis published in The Lancet Neurology
January 23, 2025 05:45 ET
|
Janssen Cilag International NV
The first investigational FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+ Nipocalimab demonstrated a...
Nipocalimab pivotal Phase 3 trial demonstrates sustained disease control in FcRn class for a broad population of myasthenia gravis patients
June 28, 2024 12:09 ET
|
Janssen Cilag International NV
First FcRn blocker to demonstrate superiority in Myasthenia Gravis - Activities of Daily Living score (MG-ADL) a over placebo when added to standard of care over 24 weeks in antibody positive...
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients
June 11, 2024 06:00 ET
|
NMD Pharma
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients Aarhus, Denmark, 11 June 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel...
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients
June 11, 2024 01:00 ET
|
NMD Pharma
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients Aarhus, Denmark, 11 June 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing...
Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
May 28, 2024 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Myasthenia Gravis (MG) Treatment Industry Forecast to 2030: A $2.5 Billion Market Dominated by Alexion Pharma, Grifols, Avadel Pharma, Novartis, Pfizer, AbbVie, and Roche
April 17, 2024 04:05 ET
|
Research and Markets
Dublin, April 17, 2024 (GLOBE NEWSWIRE) -- The "Myasthenia Gravis Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's...
NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US
March 22, 2024 07:00 ET
|
NMD Pharma
NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US Aarhus, Denmark, 22 March 2024 – NMD Pharma A/S, a...
NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US
March 22, 2024 02:00 ET
|
NMD Pharma
NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US Aarhus, Denmark, 22 March 2024 – NMD Pharma A/S, a...
NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine
March 21, 2024 07:00 ET
|
NMD Pharma
NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine ClC-1 is a chloride ion channel specifically expressed in skeletal muscle cells that normally dampens...